麝香保心丸联合阿托伐他汀治疗急性冠状动脉综合征患者的疗效及对血脂、血清MMP-8和TIMP-1的影响  

Effect of Shexiang Baoxin pill combined with atorvastatin in the treatment of patients with acute coronary syn⁃drome and influence on blood lipid,MMP-8 and TIMP-1

作　　者：董克周 林晓泼 陈春文 DONG Kezhou;LIN Xiaopo;CHEN Chunwen(Department of Emergency,Pingyang People's Hospital,Wenzhou 325400,China)

机构地区：[1]平阳县人民医院急诊科,浙江温州325400

出　　处：《全科医学临床与教育》2024年第7期620-623,共4页Clinical Education of General Practice

摘　　要：目的探讨麝香保心丸联合阿托伐他汀治疗急性冠脉综合征(ACS)患者的疗效及对血脂、血清基质金属蛋白酶8(MMP-8)和基质金属蛋白酶组织抑制因子1(TIMP-1)的影响。方法160例ACS患者随机分为观察组(n=80)和对照组(n=80)。对照组给予阿托伐他汀治疗,观察组在对照组基础上给予麝香保心丸治疗。比较两组冠脉介入疗效,总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)等血脂指标水平,MMP-8、TIMP-1、C反应蛋白(CRP)和白细胞介素6(IL-6)等炎症因子水平,左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)、左心室舒张末期容积指数(LVEDVI)及左心室射血分数(LVEF)等心功能指标水平,以及30 d主要心血管不良事件(MACE)发生情况。结果两组冠脉介入治疗总有效率比较,差异无统计学意义(χ^(2)=1.56,P>0.05);治疗后,观察组TC、TG、LDL-C水平均明显低于对照组,HDL-C水平明显高于对照组(t分别=2.30、2.03、2.57、-3.64,P均<0.05),观察组血脂达标率为43.33%,明显高于对照组血脂达标率25.00%(χ^(2)=4.48,P<0.05);治疗后,观察组MMP-8、CRP、IL-6水平及LVESV、LVEDV、LVEDVI均明显低于对照组,TIMP-1水平、LVEF明显高于对照组(t分别=2.29、2.19、8.55、2.17、2.29、2.37、-2.97、-2.40,P均<0.05);两组30 d MACE发生率比较,差异无统计学意义(χ^(2)=0.12,P>0.05)。结论麝香保心丸联合阿托伐他汀治疗ACS患者可有效改善患者血脂、心功能及降低炎症水平,利于稳定斑块。Objective To investigate the effect of Shexiang Baoxin pill combined with atorvastatin in the treatment of patients with acute coronary syndrome(ACS)and influence on blood lipid,matrix met alloproteinase 8(MMP-8)and tissue inhibitor of matrix met alloproteinase-1(TIMP-1).Methods Totally 160 patients with ACS were enrolled and randomly divided into observation group(n=80)and control group(n=80).The control group was treated with atorvas-tatin,and the observation group was treated with Shexiang Baoxin pill combined with atorvastatin.Efficacy of coronary in-tervention,blood lipid indicators levels including total cholesterol(TC),triglyceride(TG),low density lipoprotein choles-terol(LDL-C)and high density lipoprotein cholesterol(HDL-C),inflammation factors levels including MMP-8,TIMP-1,C-reactive protein(CRP)and interleukin-6(IL-6),cardiac function indicators levels including left ventricular end systolic volume(LVESV),left ventricular end diastolic volume(LVEDV),left ventricular end diastolic volume index(LVEDVI)and left ventricular ejection fraction(LVEF)were compared between two groups,as well as major adverse cardiac events(MACE)within 30 d.Results There was no statistically significant difference in the effectiveness of coronary intervention treatment between two groups(χ^(2)=1.56,P>0.05).After treatment,the levels of TC,TG,and LDL-C in the observation group were significantly lower than those in the control group,and the levels of HDL-C were signifi-cantly higher than that in the control group(t=2.30,2.03,2.57,-3.64,P<0.05).The blood lipid compliance rate in the observation group was 43.33%,which was signifi-cantly higher than 25.00%in the control group(χ^(2)=4.48,P<0.05).After treatment,the levels of MMP-8,CRP,IL-6,LVESV,LVEDV,and LVEDVI in the observation group were significantly lower than those in the control group,while the levels of TIMP-1 and LVEF were significantly higher than those in the control group(t=2.29,2.19,8.55,2.17,2.29,2.37,-2.97,-2.40,P<0.05).There was no statisti-cally significant differe

关 键 词：麝香保心丸 阿托伐他汀 急性冠状动脉综合征 血脂 基质金属蛋白酶8 基质金属蛋白酶组织抑制因子1 

分 类 号：R541.4[医药卫生—心血管疾病]